Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: Results of a prospective multicenter registry

Japanese Journal of Clinical Oncology

Volumn 44, Issue 11, 2014, Pages 1032-1039

  Satoh, Taroh ^a,b   Gemma, Akihiko ^c   Kudoh, Shoji ^d   Sakai, Fumikazu ^e   Yamaguchi, Kensei ^f   Watanabe, Toshiaki ^g   Ishiguro, Megumi ^h   Inoshiri, Shogo ⁱ   Izawa, Makiko ^j   Sugihara, Kenichi ^h   Sakata, Yuh ^k  

^a KINKI UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d Japan Anti tuberculosis Association   (Japan)

^e SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^f SAITAMA CANCER CENTER   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

ⁱ Merck Serono Co Ltd   (Japan)

^j Bristol Myers KK   (Japan)

^k Misawa City Hospital   (Japan)

more..

Author keywords

Biological therapy; Cetuximab; Chemotherapy; Colorectal cancer; Drug induced lung injury

Indexed keywords

CETUXIMAB; IRINOTECAN; STEROID; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER REGISTRY; CLINICAL FEATURE; COLORECTAL CANCER; DRUG INDUCED DISEASE; DRUG INDUCED LUNG INJURY; FEMALE; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; JAPANESE (PEOPLE); LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MEDICAL ONCOLOGIST; MORTALITY; MULTICENTER STUDY (TOPIC); PATIENT MONITORING; PROGNOSIS; PROSPECTIVE STUDY; PULMONOLOGIST; RADIOLOGIST; STEROID THERAPY; AGE; AGE DISTRIBUTION; ANTAGONISTS AND INHIBITORS; CASE REPORT; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECTS; FOLLOW UP; LIVER TUMOR; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; REGISTER; SECONDARY; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIVER NEOPLASMS; LUNG INJURY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REGISTRIES; SIGNAL TRANSDUCTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84922391352     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyu128     Document Type: Article

References (25)

1. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9.
2. Cooper JA, Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am Rev Respir Dis 1986;133:321-40.
3. Cooper JA, Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 2: noncytotoxic drugs. Am Rev Respir Dis 1986;133:488-505.
4. Tsuboi M, Le Chevailier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol 2006;23:161-70.
5. Azuma A, Kudoh S. High prevalence of drug-induced pneumonia in Japan. Jap Med Assoc J 2007;50:405-11.
6. Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008;177:1348-57.
7. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56.
8. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
9. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
10. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-9.
11. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
12. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
13. Ishiguro M, Watanabe T, Yamaguchi K, et al. A Japanese post-marketing surveillance of cetuximab (Erbituxw) in patients with metastatic colorectal cancer. Jpn J Clin Oncol 2012;42:287-94.
14. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104.
15. Hotta K, Kiura K, Tabata M, et al. Interstitial lung disease in patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005;11:417-24.
16. Sawada T, Inokuma S, Sato T, et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009;48:1069-72.
17. McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004;363:461.
18. Chou CL, Ko HW, Wang CW, Yu CT, Kuo HP, Huang CD. Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma. Chang Gung Med J 2010;33:100-5.
19. Shih YN, Chiu CH, Tsai CM, Perng RP. Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer. J Chin Med Assoc 2005;68:183-6.
20. Lin WC, Chiu CH, Liou JL, Chen YM, Perng RP, Tsai CM. Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer 2006;54:193-9.
21. Swigris JJ, Olson AL, Huie TJ, et al. Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death. Respir Med 2012;106:588-93.
22. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011;364: 1503-12.
23. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008;178:729-37.
24. Shimura T, Fuse N, Yoshino T, et al. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Ann Oncol 2010;21:2005-10.
25. Hotta K, Kimura K, Tabata M, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005;11:417-24.